Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | terminated | Phase 1 | 20 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT03318016 | Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 5 | University of Colorado, DenverOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04545333 | The clonoSEQ® Watch Registry | terminated | — | 465 | Adaptive BiotechnologiesINDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 3 | 388 | GlycoMimetics IncorporatedINDUSTRY | 9 | Jul 29, 2024 | clinicaltrials |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | terminated | Phase 1 | 5 | Roncarolo, Maria Grazia, MDOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03176277 | A Study of ONO-7475 in Patients With Acute Leukemias | terminated | Phase 1 / Phase 2 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | terminated | Phase 2 | 5 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia(PAVE) | terminated | Phase 1 | 16 | Medical College of WisconsinOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | terminated | Phase 1 | 37 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML(AML-ViVA) | terminated | Phase 2 | 10 | University Hospital RegensburgOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05410574 | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | terminated | N/A | 17 | Washington University School of MedicineOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 39 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT00779480 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002) | terminated | Phase 1 | 14 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia(AML) | terminated | Phase 3 | 9 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT02446145 | A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients(DELTA) | terminated | Phase 2 | 132 | Technische Universität DresdenOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT04968860 | Oral Health Condition and Quality of Life in Children With Leukemia | terminated | — | 9 | Paulo Sergio da Silva SantosOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05345938 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia | terminated | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04956042 | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 18 | CicloMed LLCINDUSTRY | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 6 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | terminated | Phase 1 / Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | terminated | Phase 2 | 3 | Prof. Christina PetersOTHER | 10 | Jan 16, 2024 | clinicaltrials |
| NCT02580981 | Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses | terminated | N/A | 21 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | terminated | Phase 1 | 13 | University of WashingtonOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Intellia TherapeuticsINDUSTRY | 2 | Dec 28, 2023 | clinicaltrials |
| NCT04803123 | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL | terminated | Early Phase 1 | 3 | Dorothy Sipkins, MD, PhDOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | terminated | Phase 2 | 104 | Sumitomo Pharma America, Inc.INDUSTRY | 4 | Nov 15, 2023 | clinicaltrials |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | terminated | Phase 2 | 11 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 72 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | terminated | Phase 1 | 67 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 2 | Oct 13, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | terminated | Phase 2 | 6 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 2 | Sep 29, 2023 | clinicaltrials |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2024source: clinicaltrials